Table 3.

Efficacy comparisons between subgroups during evaluation

	Number of patients	Hemoglobin (g/dL)	Hemoglobin fluctuation (g/dL)	Overall stability (%)	Average monthly dose (µg)	% dose changes	Dose changes per patient
All	2060	11.4	0.48	78	131.3	18.0	0.4
Target group L	935	11.2	0.46	80	124.7	19.1	0.4
Target group U	1125	11.6	0.50 b	77	136.9 b	17.1	0.3
Female	874	11.4	0.48	80	131.0	17.2	0.3
Male	1186	11.5	0.48	77	131.6	18.5	0.4
Age <65	1090	11.5	0.5	77	131.5	18.4	0.4
Age ≥65	932	11.4	0.45 a	80	129.3	17.5	0.4
NT-proBNP <5000	975e	11.4	0.47	78	124.3	18.1	0.4
NT-proBNP ≥5000	624e	11.4	0.49	80	138.0 c	18.2	0.4
No CV risk	283	11.5	0.51	78	127.8	17.7	0.4
Cardiac risk	565	11.4	0.46 d	78	136.2	18.0	0.4
Vascular risk	1675	11.4	0.48	79	132.2	18.1	0.4
Diabetes at baseline	535	11.3	0.47	76	132.5	17.4	0.3

Italicized values indicate significant differences (p < 0.01) between subgroups: ^a p < 0.001; ^b p = 0.001; ^c p = 0.002; ^d p = 0.01

^eNT-proBNP was not measured for all patients

CV cardiovascular, L lower, NT-proBNP N-terminal pro-B-type natriuretic peptide, U upper